華廈眼科(301267.SZ):公司實際控制人、董事長蘇慶燦被留置
格隆匯12月7日丨華廈眼科(301267.SZ)公佈,公司於2023年12月6日收到通知,公司實際控制人、董事長蘇慶燦先生因個人原因被上海市監察委員會實施留置。截至本公吿披露日,公司未收到有權機關對公司的任何調查或配合調查文件。
公司擁有完善的治理結構及內部控制機制,已對相關事項做了妥善安排,公司將按照《公司法》、《深圳證券交易所股票上市規則》、《上市公司治理準則》及《公司章程》等法律法規和相關制度規範運作。截至本公吿披露日,公司控制權未發生變化,除蘇慶燦先生外的公司其他全部董事、監事、高級管理人員目前均正常履職,公司生產經營及管理情況正常,本事項不會對公司正常生產經營產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.